Sirolimus plus palbociclib and fulvestrant for advanced breast cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a new combination of three drugs (sirolimus, palbociclib, and fulvestrant) for people with a certain type of advanced breast cancer that is hormone receptor-positive and HER2-negative. The goal is to see if adding sirolimus can help control the cancer when standard hormone therapy is no longer working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and, if female, past menopause.
- Your breast cancer is advanced, hormone receptor-positive, and HER2-negative.
- You have not received chemotherapy or a CDK4/6 inhibitor for your advanced cancer.
- You have had prior hormone therapy (like tamoxifen or an aromatase inhibitor) and your cancer worsened during or within 12 months after finishing it.
- You have at least one tumor that can be measured on scans (for the expansion part of the trial).
- You are in good enough health to have a daily activity level of 0 or 1 on a standard scale.
- You have not had prior treatment with fulvestrant or drugs that block the PI3K/AKT/mTOR pathway.
- You do not have serious lung disease, uncontrolled fluid buildup, or certain digestive problems.
- You are not allergic to any of the study drugs or their ingredients.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, HRS-6209, combined with different hormone treatments (fulvestrant, letrozole, HRS-8080, or HRS-1358) for people with advanced breast cancer that has spread or cannot be surgically removed and has worsened after previous treatments.
This trial tests a new drug called FWD1802 combined with other treatments for people with a certain type of advanced breast cancer (ER-positive, HER2-negative). It aims to find better options if standard treatments have stopped working or aren't suitable.
This Phase 2 trial tests whether adding everolimus to standard first-line hormone (endocrine) therapy can better control a certain type of advanced breast cancer. It is designed for people whose tumor matches a specific “SNF1 subtype.”
This trial tests two experimental drugs, SI-B003 and BL-B01D1 plus SI-B003, for people with HER2-negative breast cancer that has spread or cannot be removed by surgery. It is for those who have tried standard treatments or cannot have them.
This trial tests a new form of the drug sirolimus (bound to albumin) combined with two other drugs (palbociclib and fulvestrant) for advanced breast cancer. It aims to see if this combination is safe and effective for people with the HR-positive, HER2-negative subtype.
This trial tests a new combination treatment (sirolimus and fulvestrant) for people with advanced breast cancer that is HR+ and HER2-. It may help if your previous hormonal therapy plus a CDK4/6 inhibitor is no longer working.
Hear when a new Advanced HR - Positive, HER2 - Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.